About this episode

This episode discusses the SARC-041 trial and its implications for treating advanced dedifferentiated liposarcoma.

This week’s episode will be focusing on an ASCO 2026 Plenary abstract, SARC 041. SARC041 is the first positive phase 3 randomized controlled trial of a CDK4/6 inhibitor in advanced dedifferentiated liposarcoma (DDLPS), demonstrating that abemaciclib significantly improves progression-free survival compared to placebo.

More episodes of Two Onc Docs

• DLBCL 2026 UPDATE · July 20, 2026 · 13 min
• Wellness in Oncology with Dr. Laura Vater · July 13, 2026 · 24 min
• Transitioning from Fellow to Attending with Dr. Laura Vater · June 29, 2026 · 19 min
• ASCO Annual Meeting 2026 GU Recap · June 15, 2026 · 15 min

Explore listener stats, chart rankings, contacts and more on the Two Onc Docs podcast page.